Abstract Library

#3054 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour: Nutrition in NETs Study

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) can adversely affect nutritional status. Cross-sectional studies report up to 25% of GEP NET patients are malnourished and dietary change may be prevalent. Nevertheless, clinical guidelines lack advice on nutrition management.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Laing E

Authors: Laing E, Kiss N, Michael M, Krishnasamy M, Gough K,

Keywords: neuroendocrine, nutrition, malnutrition, weight change, symptoms,

#3009 OPERA: Observational Study of Perception of Information and Quality of Life in Patients with Gastroenteropancreatic NeuroEndocrine TumoRs Starting LAnreotide Autogel–Baseline Characteristics

Introduction: Information provided to patients (pts) with neuroendocrine tumors (NETs) about burden and treatment proposed may influence pts’ adherence to treatment, outpatient monitoring and quality of life (QoL), but can also cause anxiety.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Hautefeuille V

Authors: Hautefeuille V, Do Cao C, Coriat R, Dominguez S, Mineur L,

Keywords: Patients’ perception of information, Quality of Life, Lanreotide,

#2828 G3 Neuroendocrine Tumours and Carcinomas: Clinicopathological Features for Distinct Entities

Introduction: The 2019 WHO subclassified the grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) into neuroendocrine carcinoma (NEC) or tumors (G3 NET). Yet, few data exist on clinical and treatment profiles for G3 NET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Taboada R

Authors: Taboada R, Claro L, Campos F, Felismino T, de Jesus V,

Keywords: neuroendocrine, high grade, clinicopathological, carcinoma, G3,

#2823 Peptide Receptor Radionuclide Therapy in Rectal Neuroendocrine Tumours

Introduction: Neuroendocrine tumours (NETs) arising from the rectum are more common in the Asian population. Current treatment options include somatostatin analogues, chemotherapy, and more recently, peptide-receptor radionuclide therapy (PRRT). Peptide receptor radionuclide therapy (PRRT) has been shown to be effective in the treatment of advanced gastroenteropancreatic (GEP) tumours with minimal adverse effects. Studies have also suggested that rectal NETs show good response to PRRT, better than GEP NETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Tham W, Huang H, Tai W, Yan X, Ng C,

Keywords: Neuroendocrine tumours, PRRT,

#2808 Clinical Features and Quality of Life in Patients with Gastroenteropancreatic Neuroendocrine Tumors from Chile

Introduction: Clinical features of Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs) and their repercussions on health-related quality of life (HRQoL) have not been widely studied in Hispanic populations.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Carrillo D

Authors: Carrillo D, Munoz-Anguita G, Madison A, Retamal I, Pinto M,

Keywords: Neuroendocrine, Carcinoid, Health-related quality of life.,